1. Home
  2. HURA vs QH Comparison

HURA vs QH Comparison

Compare HURA & QH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • QH
  • Stock Information
  • Founded
  • HURA 2009
  • QH 2012
  • Country
  • HURA United States
  • QH China
  • Employees
  • HURA N/A
  • QH N/A
  • Industry
  • HURA
  • QH Business Services
  • Sector
  • HURA
  • QH Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • QH Nasdaq
  • Market Cap
  • HURA 122.0M
  • QH 115.7M
  • IPO Year
  • HURA N/A
  • QH 2020
  • Fundamental
  • Price
  • HURA $3.06
  • QH $0.11
  • Analyst Decision
  • HURA Strong Buy
  • QH
  • Analyst Count
  • HURA 2
  • QH 0
  • Target Price
  • HURA $11.50
  • QH N/A
  • AVG Volume (30 Days)
  • HURA 773.7K
  • QH 19.8M
  • Earning Date
  • HURA 08-14-2025
  • QH 08-27-2025
  • Dividend Yield
  • HURA N/A
  • QH N/A
  • EPS Growth
  • HURA N/A
  • QH N/A
  • EPS
  • HURA N/A
  • QH 0.01
  • Revenue
  • HURA N/A
  • QH $417,431,053.00
  • Revenue This Year
  • HURA N/A
  • QH N/A
  • Revenue Next Year
  • HURA N/A
  • QH N/A
  • P/E Ratio
  • HURA N/A
  • QH $12.79
  • Revenue Growth
  • HURA N/A
  • QH N/A
  • 52 Week Low
  • HURA $1.80
  • QH $0.09
  • 52 Week High
  • HURA $8.63
  • QH $2.27
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • QH 22.51
  • Support Level
  • HURA N/A
  • QH $0.09
  • Resistance Level
  • HURA N/A
  • QH $0.12
  • Average True Range (ATR)
  • HURA 0.00
  • QH 0.02
  • MACD
  • HURA 0.00
  • QH -0.00
  • Stochastic Oscillator
  • HURA 0.00
  • QH 46.38

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

Share on Social Networks: